GeminiBio Appoints Matt Stober to Board of Directors
Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of raw materials to the biopharmaceutical and advanced therapy industries, has announced the appointment of Matthew Stober to its Board of Directors. This strategic addition to the board is expected to provide valuable insights into biologics manufacturing workflows and support the company’s continued growth in the industry.
A portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Fort Lauderdale-based healthcare private equity firm, GeminiBio specializes in providing critical raw materials such as serum, customized media, buffers, and process liquids. These products are vital to the research and production of advanced therapeutic technologies, including mRNA, adeno-associated virus (AAV), monoclonal antibody, and cell therapy development.
A Strategic Addition to the Board
The appointment of Matt Stober to the GeminiBio Board underscores the company’s commitment to innovation and operational excellence in biologics manufacturing. With his deep expertise in the biopharmaceutical sector, Stober will offer unique customer-oriented perspectives on workflow challenges and help identify opportunities for GeminiBio to streamline processes and improve efficiencies.
Stober brings an extensive background in the biopharma, cell therapy, and gene therapy industries, having held executive leadership positions at several top-tier pharmaceutical companies, including Novartis, Merck, Pfizer, and GlaxoSmithKline. Currently serving as the CEO of Abzena, a contract development and manufacturing organization (CDMO) specializing in biologics and bioconjugates, Stober has a strong track record of optimizing production processes and improving manufacturing efficiencies.
Cory Stevenson, Executive Chairman of the GeminiBio Board, expressed his enthusiasm for Stober’s appointment:
“With Matt’s extensive experience across various therapeutic manufacturing processes and his working knowledge of the critical role raw materials play—especially ready-to-use solutions—in enhancing production efficiency, we look forward to leveraging his insights. His deep understanding from a user’s perspective will be invaluable as we work to drive growth and expand our market presence.”
Enhancing Supplier-Manufacturer Collaboration
The biopharmaceutical, cell therapy, and gene therapy sectors depend heavily on seamless collaboration between suppliers and manufacturers to optimize process efficiencies. This partnership ensures the timely and cost-effective production of life-saving therapeutics. Stober recognizes the critical role companies like GeminiBio play in this ecosystem.
“Suppliers like GeminiBio serve as the backbone of the biopharma, cell therapy, and gene therapy industries,” said Stober. “These industries thrive on successful partnerships that enable optimized processes, resulting in time and material cost savings. It is crucial that we work together to deliver life-saving therapeutics efficiently and affordably. I look forward to collaborating with the Board and Brian Parker, GeminiBio’s CEO, to achieve these shared goals.”
In addition to his role at GeminiBio, Stober also serves on the boards of Leiters Health, Istari Oncology, and CastleVax, further showcasing his commitment to advancing innovation and operational excellence across the pharmaceutical and biotechnology sectors.
About GeminiBio
Founded in 1985, GeminiBio has built a reputation as a trusted partner in the biopharmaceutical and advanced therapy industries. The company provides essential raw materials used in cell therapy, gene therapy, and biotherapeutics manufacturing, offering products such as serum, customized media and buffer solutions, and process liquids.
GeminiBio is headquartered in West Sacramento, California, where it operates a state-of-the-art facility spanning 57,000 square feet of current Good Manufacturing Practice (cGMP) manufacturing space. This facility is designed to maintain strict quality control measures, with segregated areas for animal-origin-free and animal-component manufacturing. The company is ISO 13485:2016 certified and is an FDA-registered Class 1 Medical Device Manufacturer, ensuring compliance with 21 CFR Part 820 regulatory standards.
GeminiBio’s mission is to support its customers in accelerating the development of life-enhancing biotherapeutics by improving and streamlining their cell culture and process liquid manufacturing workflows. By offering high-quality, scalable, and innovative solutions, the company enables researchers and manufacturers to advance their work with greater efficiency and reliability.
About BelHealth Investment Partners
BelHealth Investment Partners is a private equity firm based in Fort Lauderdale, Florida, focused on investing in the healthcare sector. The firm primarily targets lower middle-market companies, acquiring majority positions in entrepreneur-owned businesses that can benefit from BelHealth’s extensive industry experience, strategic oversight, and operational expertise.
BelHealth’s investment approach involves partnering with management teams to drive growth, operational improvements, and market expansion. By leveraging its deep knowledge of the healthcare industry, the firm aims to enhance the value of its portfolio companies while fostering innovation and improving patient outcomes.
